However, we find this unlikely when considering that ADAM17 is the only known target of Marimastat which is believed to be involved in cleavage of CD16320, and even further unlikely when considering that we observed a strong correlation between ADAM17 activity and sCD163 levels in the peripheral blood of stroke patients in vivo. The gene discussed is CD163; the disease is stroke disorder.